303 related articles for article (PubMed ID: 23433769)
1. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis.
Stockley R; De Soyza A; Gunawardena K; Perrett J; Forsman-Semb K; Entwistle N; Snell N
Respir Med; 2013 Apr; 107(4):524-33. PubMed ID: 23433769
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis.
Elborn JS; Perrett J; Forsman-Semb K; Marks-Konczalik J; Gunawardena K; Entwistle N
Eur Respir J; 2012 Oct; 40(4):969-76. PubMed ID: 22267768
[TBL] [Abstract][Full Text] [Related]
3. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
Kuna P; Jenkins M; O'Brien CD; Fahy WA
Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
[TBL] [Abstract][Full Text] [Related]
4. A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium.
Vogelmeier C; Aquino TO; O'Brien CD; Perrett J; Gunawardena KA
COPD; 2012 Apr; 9(2):111-20. PubMed ID: 22458939
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: A randomized controlled trial.
Watz H; Nagelschmitz J; Kirsten A; Pedersen F; van der Mey D; Schwers S; Bandel TJ; Rabe KF
Pulm Pharmacol Ther; 2019 Jun; 56():86-93. PubMed ID: 30917927
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of AZD9668, an oral neutrophil elastase inhibitor, in healthy volunteers and patients with COPD.
Gunawardena KA; Gullstrand H; Perrett J
Int J Clin Pharmacol Ther; 2013 Apr; 51(4):288-304. PubMed ID: 23391369
[TBL] [Abstract][Full Text] [Related]
7. AZD9668: pharmacological characterization of a novel oral inhibitor of neutrophil elastase.
Stevens T; Ekholm K; Gränse M; Lindahl M; Kozma V; Jungar C; Ottosson T; Falk-Håkansson H; Churg A; Wright JL; Lal H; Sanfridson A
J Pharmacol Exp Ther; 2011 Oct; 339(1):313-20. PubMed ID: 21791628
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of Computed Tomography in a Multicenter COPD Trial: A Study of the Effect of AZD9668 on Structural Airway Changes.
Nordenmark LH; Taylor R; Jorup C
Adv Ther; 2015 Jun; 32(6):548-66. PubMed ID: 26043724
[TBL] [Abstract][Full Text] [Related]
9. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis.
De Soyza A; Pavord I; Elborn JS; Smith D; Wray H; Puu M; Larsson B; Stockley R
Eur Respir J; 2015 Oct; 46(4):1021-32. PubMed ID: 26341987
[TBL] [Abstract][Full Text] [Related]
10. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.
Bilton D; Tino G; Barker AF; Chambers DC; De Soyza A; Dupont LJ; O'Dochartaigh C; van Haren EH; Vidal LO; Welte T; Fox HG; Wu J; Charlton B;
Thorax; 2014 Dec; 69(12):1073-9. PubMed ID: 25246664
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.
Martin SL; Downey D; Bilton D; Keogan MT; Edgar J; Elborn JS;
Pediatr Pulmonol; 2006 Feb; 41(2):177-83. PubMed ID: 16372352
[TBL] [Abstract][Full Text] [Related]
12. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis.
Bilton D; Daviskas E; Anderson SD; Kolbe J; King G; Stirling RG; Thompson BR; Milne D; Charlton B;
Chest; 2013 Jul; 144(1):215-225. PubMed ID: 23429964
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis.
Chalmers JD; Moffitt KL; Suarez-Cuartin G; Sibila O; Finch S; Furrie E; Dicker A; Wrobel K; Elborn JS; Walker B; Martin SL; Marshall SE; Huang JT; Fardon TC
Am J Respir Crit Care Med; 2017 May; 195(10):1384-1393. PubMed ID: 27911604
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.
Chalmers JD; Haworth CS; Metersky ML; Loebinger MR; Blasi F; Sibila O; O'Donnell AE; Sullivan EJ; Mange KC; Fernandez C; Zou J; Daley CL;
N Engl J Med; 2020 Nov; 383(22):2127-2137. PubMed ID: 32897034
[TBL] [Abstract][Full Text] [Related]
15. In vivo study of indomethacin in bronchiectasis: effect on neutrophil function and lung secretion.
Llewellyn-Jones CG; Johnson MM; Mitchell JL; Pye A; Okafor VC; Hill SL; Stockley RA
Eur Respir J; 1995 Sep; 8(9):1479-87. PubMed ID: 8575572
[TBL] [Abstract][Full Text] [Related]
16. Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: a randomised controlled trial.
Dahl R; Titlestad I; Lindqvist A; Wielders P; Wray H; Wang M; Samuelsson V; Mo J; Holt A
Pulm Pharmacol Ther; 2012 Apr; 25(2):169-77. PubMed ID: 22306193
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil elastase inhibitors: recent advances in the development of mechanism-based and nonelectrophilic inhibitors.
Sjö P
Future Med Chem; 2012 Apr; 4(5):651-60. PubMed ID: 22458683
[TBL] [Abstract][Full Text] [Related]
18. The response of patients with purulent bronchiectasis to antibiotics for four months.
Hill SL; Burnett D; Hewetson KA; Stockley RA
Q J Med; 1988 Feb; 66(250):163-73. PubMed ID: 3262882
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial.
Cipolla D; Zhang J; Korkmaz B; Chalmers JD; Basso J; Lasala D; Fernandez C; Teper A; Mange KC; Perkins WR; Sullivan EJ
Respir Res; 2023 May; 24(1):133. PubMed ID: 37198686
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of azithromycin in the treatment of bronchiectasis.
Lourdesamy Anthony AI; Muthukumaru U
Respirology; 2014 Nov; 19(8):1178-82. PubMed ID: 25183304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
